Advanced search
Publication Cover
Expert Review of Hematology Volume 17, 2024 - Issue 4-5
Submit an article Journal homepage
105
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia

Yizhou Penga Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-8910-4847View further author information
ORCID Icon,
Jinjin Huanga Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Jin Yina Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Fankai Menga Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Yang Caoa Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Liang Huanga Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Dengju Lia Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Yicheng Zhanga Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Donghua Zhanga Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Li Menga Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
,
Zhiqiang Hanb Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaView further author information
&
Zhenya Honga Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4064-8907View further author information
ORCID Icon show all
Pages 173-180 | Received 19 Sep 2023, Accepted 19 Mar 2024, Published online: 24 Apr 2024

References

  • Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015 May;100(5):653–661. doi: 10.3324/haematol.2014.118588
  • Ravandi F, O’Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 1;121(23):4158–4164. doi: 10.1002/cncr.29646
  • Short NJ, Kantarjian HM, Ravandi F, et al. Long-term safety and efficacy of hyper-CVAD plus ponatinib as frontline therapy for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):283–283. doi: 10.1182/blood-2019-125146
  • Jabbour E, Haddad FG, Short NJ, et al. Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol. 2022 Sep 1;8(9):1340–1348. doi: 10.1001/jamaoncol.2022.2398
  • Ravandi F, Othus M, O’Brien SM, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 2016 Dec 27;1(3):250–259. doi: 10.1182/bloodadvances.2016001495
  • Liu B, Wang Y, Zhou C, et al. Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up. Ann Hematol. 2019 Mar;98(3):633–645. doi: 10.1007/s00277-019-03594-1
  • Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015 Aug 6;126(6):746–756. doi: 10.1182/blood-2015-03-636548
  • Kantarjian H, Short NJ, Jain N, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 Mar;98(3):493–501. doi: 10.1002/ajh.26816
  • Short N, Kantarjian H, Jain N, et al. Ponatinib and Blinatumomab for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a subgroup analysis from a phase II study. Blood. 2022;140(Supplement 1):513–515. doi: 10.1182/blood-2022-157775
  • Foa R, Bassan R, Elia L, et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2023;42(8):881–885. doi: 10.1200/JCO.23.01075 Dec 21:JCO2301075.
  • Martinelli G, Papayannidis C, Piciocchi A, et al. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv. 2022 Mar 22;6(6):1742–1753. doi: 10.1182/bloodadvances.2021004821
  • Wieduwilt MJ, Yin J, Wetzler M, et al. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 Nov 23;5(22):4691–4700. doi: 10.1182/bloodadvances.2021004813
  • Ribera JM, Garcia-Calduch O, Ribera J, et al. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022 Sep 27;6(18):5395–5402. doi: 10.1182/bloodadvances.2022007764
  • Liu D, Zhao J, Song Y, et al. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol. 2019 Feb 8;12(1):15. doi: 10.1186/s13045-019-0703-z
  • Wang J, Jiang Q, Xu L-P, et al. Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Biology Of Blood And Marrow Transplantation. 2018;24(4):741–750. doi: 10.1016/j.bbmt.2017.12.777
  • Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783–1796. doi: 10.1056/NEJMoa1306494
  • Nicolini FE, Basak GW, Kim DW, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 1;123(15):2875–2880. doi: 10.1002/cncr.30558
  • Gu B, Shi BY, Zhang X, et al. Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells. Bone Marrow Transplant. 2021 Jan;56(1):91–100. doi: 10.1038/s41409-020-0982-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.